FY2024 Earnings Estimate for BIO Issued By Zacks Research

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Zacks Research raised their FY2024 EPS estimates for shares of Bio-Rad Laboratories in a note issued to investors on Wednesday, December 18th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings per share of $10.20 for the year, up from their previous forecast of $10.18. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $10.29 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q4 2024 earnings at $2.79 EPS, Q1 2025 earnings at $2.30 EPS, Q2 2025 earnings at $3.01 EPS, FY2025 earnings at $11.46 EPS and Q1 2026 earnings at $3.09 EPS.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings results on Wednesday, October 30th. The medical research company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.16 by $0.85. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. The firm had revenue of $649.70 million during the quarter, compared to the consensus estimate of $628.18 million. During the same quarter last year, the firm earned $2.33 earnings per share. The company’s revenue for the quarter was up 2.8% on a year-over-year basis.

BIO has been the subject of several other research reports. Royal Bank of Canada increased their price target on Bio-Rad Laboratories from $369.00 to $481.00 and gave the company an “outperform” rating in a research note on Monday, December 9th. Citigroup increased their target price on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Wells Fargo & Company started coverage on shares of Bio-Rad Laboratories in a report on Tuesday, August 27th. They set an “equal weight” rating and a $340.00 price target for the company. Finally, StockNews.com raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Friday, November 1st. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Bio-Rad Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $394.20.

Bio-Rad Laboratories Stock Up 0.6 %

Shares of NYSE:BIO opened at $325.94 on Friday. The firm has a market cap of $9.13 billion, a P/E ratio of -11.93 and a beta of 0.90. Bio-Rad Laboratories has a 12-month low of $262.12 and a 12-month high of $387.99. The business has a fifty day simple moving average of $340.91 and a 200 day simple moving average of $322.11. The company has a quick ratio of 4.52, a current ratio of 6.14 and a debt-to-equity ratio of 0.16.

Institutional Investors Weigh In On Bio-Rad Laboratories

A number of hedge funds have recently added to or reduced their stakes in BIO. Avior Wealth Management LLC grew its position in shares of Bio-Rad Laboratories by 3.3% during the 3rd quarter. Avior Wealth Management LLC now owns 999 shares of the medical research company’s stock worth $334,000 after buying an additional 32 shares during the period. UMB Bank n.a. lifted its position in shares of Bio-Rad Laboratories by 140.6% during the 3rd quarter. UMB Bank n.a. now owns 77 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 45 shares during the period. Capital Advisors Ltd. LLC boosted its stake in Bio-Rad Laboratories by 193.8% during the second quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company’s stock worth $26,000 after acquiring an additional 62 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in Bio-Rad Laboratories by 9.5% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 947 shares of the medical research company’s stock worth $259,000 after purchasing an additional 82 shares during the period. Finally, Quarry LP increased its stake in Bio-Rad Laboratories by 38.1% in the third quarter. Quarry LP now owns 297 shares of the medical research company’s stock valued at $99,000 after purchasing an additional 82 shares in the last quarter. 65.24% of the stock is currently owned by institutional investors.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.